Cytovation

Cytovation develops precision medicines for patients with solid tumors, specifically those driven by the Wnt/β-catenin signaling pathway. The company utilizes novel peptide engineering to guide and stimulate the immune system to recognize and eradicate cancerous cells. Its technology is designed to address the needs of cancer patients who do not currently benefit from existing immunotherapy treatments.